Search

Your search keyword '"Pacquement H"' showing total 264 results
Start Over Author "Pacquement H"
264 results on '"Pacquement H"'

1. P44 - Colorectal cancer screening participation in childhood cancer survivors: a report from the French Childhood Cancer Survivors Study (FCCSS)

Author

Ouanounou, J., primary, Bejarano-Quisoboni, D., additional, Bougas, N., additional, Allodji, R., additional, Vu-Bezin, G., additional, Souchard, V., additional, Fayech, C., additional, Dumas, A., additional, Journy, N., additional, Demoor-Goldschmidt, C., additional, Pacquement, H., additional, Pluchart, C., additional, Bondiau, PY., additional, Quintin, C., additional, Dufour, C., additional, Valteau-Couanet, D., additional, De Vathaire, F., additional, and Fresneau, B., additional

Published
2024
Full Text
View/download PDF

5. Mise en place de recommandations thérapeutiques pour la prise en charge des neutropénies fébriles chez les enfants atteints de cancer : expérience du RIFHOP

Author

Le Carrer, L., Saulpic, J., Dubrel, M., Serinet, M.O., Pacquement, H., Raimondo, G., Tabone, M.D., Trioche, P., Mesples, B., Furioli, J., Perdereau, S., Seaumes, H., Guillon, M., Guillaumat, C., Chavlon Demersay, A., Chevallier, B., Brethon, B., Ferry, C., Gouraud, F., Belloy, M., Bensaid, P., Dallot, C., Pellegrino, B., Sarda, H., Michon, J., and Dufour, C.

Published
2014
Full Text
View/download PDF

6. ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT

Author

d’Hautefeuille, C., primary, Abbou, S., additional, El-Gourari-Miaz, L., additional, Lambilliotte, A., additional, Renard, C., additional, Landman-Parker, J., additional, Gourdon, S., additional, Metayer, L., additional, Leblanc, T., additional, Pacquement, H., additional, Rabian, F., additional, Verschuur, A., additional, Brasme, J., additional, Millot, F., additional, Pagnier, A., additional, Buchbinder, N., additional, Rorhlich, P., additional, Minard-Colin, V., additional, Brugières, L., additional, Ducassou, S., additional, and Rigaud, C., additional

Published
2022
Full Text
View/download PDF

8. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma

Author

Prokoph, N, Probst, N, Lee, L, Monahan, J, Matthews, J, Liang, H, Bahnsen, K, Montes-Mojarro, I, Karaca-Atabay, E, Sharma, G, Malik, V, Larose, H, Forde, S, Ducray, S, Lobello, C, Wang, Q, Luan, S, Pospisilova, S, Gambacorti Passerini, C, Burke, G, Pervez, S, Attarbaschi, A, Janikova, A, Pacquement, H, Landman-Parker, J, Lambilliotte, A, Schleiermacher, G, Klapper, W, Jauch, R, Woessmann, W, Vassal, G, Kenner, L, Merkel, O, Mologni, L, Chiarle, R, Brugieres, L, Geoerger, B, Barbieri, I, Turner, S, Prokoph N., Probst N. A., Lee L. C., Monahan J. M., Matthews J. D., Liang H. -C., Bahnsen K., Montes-Mojarro I. A., Karaca-Atabay E., Sharma G. G., Malik V., Larose H., Forde S. D., Ducray S. P., Lobello C., Wang Q., Luan S. -L., Pospisilova S., Gambacorti Passerini C., Burke G. A. A., Pervez S., Attarbaschi A., Janikova A., Pacquement H., Landman-Parker J., Lambilliotte A., Schleiermacher G., Klapper W., Jauch R., Woessmann W., Vassal G., Kenner L., Merkel O., Mologni L., Chiarle R., Brugieres L., Geoerger B., Barbieri I., Turner S. D., Prokoph, N, Probst, N, Lee, L, Monahan, J, Matthews, J, Liang, H, Bahnsen, K, Montes-Mojarro, I, Karaca-Atabay, E, Sharma, G, Malik, V, Larose, H, Forde, S, Ducray, S, Lobello, C, Wang, Q, Luan, S, Pospisilova, S, Gambacorti Passerini, C, Burke, G, Pervez, S, Attarbaschi, A, Janikova, A, Pacquement, H, Landman-Parker, J, Lambilliotte, A, Schleiermacher, G, Klapper, W, Jauch, R, Woessmann, W, Vassal, G, Kenner, L, Merkel, O, Mologni, L, Chiarle, R, Brugieres, L, Geoerger, B, Barbieri, I, Turner, S, Prokoph N., Probst N. A., Lee L. C., Monahan J. M., Matthews J. D., Liang H. -C., Bahnsen K., Montes-Mojarro I. A., Karaca-Atabay E., Sharma G. G., Malik V., Larose H., Forde S. D., Ducray S. P., Lobello C., Wang Q., Luan S. -L., Pospisilova S., Gambacorti Passerini C., Burke G. A. A., Pervez S., Attarbaschi A., Janikova A., Pacquement H., Landman-Parker J., Lambilliotte A., Schleiermacher G., Klapper W., Jauch R., Woessmann W., Vassal G., Kenner L., Merkel O., Mologni L., Chiarle R., Brugieres L., Geoerger B., Barbieri I., and Turner S. D.

Abstract

Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor-relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance-specific relapse.

Published
2020

13. Malformations, Genetic Abnormalities, and Wilms Tumor

Author

Dumoucel, S., Gauthier-Villars, M., Stoppa-Lyonnet, D., Parisot, P., Brisse, H., Philippe-Chomette, P., Sarnacki, S., Boccon-Gibod, L., Rossignol, S., Baumann, C., Aerts, I., Bourdeaut, F., Doz, F., Orbach, D., Pacquement, H., Michon, J., and Schleiermacher, G.

Published
2014
Full Text
View/download PDF

15. Real-life experience of multisciplinary pediatric lymphoma tumor board: decision’s impact on Hodgkin Lymphoma treatment choice and results

Author

Potier, A, additional, Montravers, F, additional, Ducou Le Pointe, H, additional, Leblanc, T, additional, Pacquement, H, additional, Brugieres, L, additional, Rigaud, C, additional, Dourthe, M E, additional, Brice, P, additional, Martin, V, additional, Boudjemaa, S, additional, Helfre, S, additional, and Landman-Parker, J, additional

Published
2020
Full Text
View/download PDF

17. 114 - ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT

Author

d’Hautefeuille, C., Abbou, S., El-Gourari-Miaz, L., Lambilliotte, A., Renard, C., Landman-Parker, J., Gourdon, S., Metayer, L., Leblanc, T., Pacquement, H., Rabian, F., Verschuur, A., Brasme, J., Millot, F., Pagnier, A., Buchbinder, N., Rorhlich, P., Minard-Colin, V., Brugières, L., Ducassou, S., and Rigaud, C.

Published
2022
Full Text
View/download PDF

22. Risk Factors of Small Final Height in Survivors of Childhood Cancer, Importance of the Irradiation Dose at the Hypophysis Gland

Author

Demoor-Goldschmidt, C., primary, Allodji, R., additional, Journy, N., additional, Rubino, C., additional, Zrafi, W., additional, Veres, C., additional, Diallo, I., additional, Thomas-Teinturier, C., additional, Bolle, S., additional, Berchery, D., additional, Haddy, N., additional, Pacquement, H., additional, Fresneau, B., additional, and De Vathaire, F., additional

Published
2019
Full Text
View/download PDF

24. Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines

Author

la Monneraye, Yvan, primary, Michon, J., additional, Pacquement, H., additional, Aerts, I., additional, Orbach, Daniel., additional, Doz, F., additional, Bourdeaut, F., additional, Sarnacki, S., additional, Philippe‐Chomette, P., additional, Audry, G., additional, Coulomb, A., additional, Fréneaux, P., additional, Klijanienko, J., additional, Berrebi, D., additional, Zucker, J.‐M., additional, Schleiermacher, G., additional, and Brisse, H.J., additional

Published
2019
Full Text
View/download PDF

28. OC-0600: Long term risk of stroke after childhood cancer radiotherapy

Author

De Vathaire, F., primary, El - Fayech, C., additional, Haddy, N., additional, Allodji, R., additional, Veres, C., additional, Llanas, D., additional, Journy, N., additional, Souchard, V., additional, Rubino, C., additional, Pacquement, H., additional, Teinturier, C., additional, Fresneau, B., additional, Vu-Bezin, G., additional, Bolle, S., additional, Mazal, A., additional, Poortmans, P., additional, Deutsch, E., additional, and Diallo, I., additional

Published
2018
Full Text
View/download PDF

31. Use of Off-Label Targeted Therapies in Refractory Sarcomas: Analysis of Pediatric Data from the French Registry Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes

Author

Bertrand, A., primary, Libbrecht, C., primary, Corradini, N., primary, Pacquement, H., primary, Gentet, J., primary, Lervat, C., primary, Girodet, M., primary, Bouclier, L., primary, Ray-Coquard, I., primary, Marec-Berard, P., primary, and Garnier, Nathalie, additional

Published
2016
Full Text
View/download PDF

32. Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines

Author

Seror, E., primary, Donadieu, J., additional, Pacquement, H., additional, Abbou, S., additional, Lambilliotte, A., additional, Schell, M., additional, Curtillet, C., additional, Gandemer, V., additional, Pasquet, M., additional, Aladjidi, N., additional, Lutz, P., additional, Schmitt, C., additional, Deville, A., additional, Minckes, O., additional, Vanier, J P., additional, Armari-Alla, C., additional, Thomas, C., additional, Gorde-Grosjean, S., additional, Millot, F., additional, Blouin, P., additional, Garnier, N., additional, Coze, C., additional, Devoldere, C., additional, Reguerre, Y., additional, Helfre, S., additional, Claude, L., additional, Clavel, J., additional, Oberlin, O., additional, Landman-Parker, J., additional, and Leblanc, T., additional

Published
2016
Full Text
View/download PDF

33. Trajectoires scolaires après un cancer pédiatrique : une contribution à l’hypothèse de la sélection par la santé

Author

Dumas, A., primary, Berger, C., additional, Auquier, P., additional, Michel, G., additional, Vassal, G., additional, Valteau-Couanet, D., additional, Fresneau, B., additional, Thouvenin-Doulet, S., additional, Casagranda, L., additional, Pacquement, H., additional, El-Fayech, C., additional, Oberlin, O., additional, Guibout, C., additional, and De Vathaire, F., additional

Published
2016
Full Text
View/download PDF

34. Zoledronate Does not Reduce the Risk of Treatment Failure in Osteosarcoma: Results of the French Multicentre Os2006 Randomised Trial

Author

Piperno-Neumann, S., primary, Le Deley, M., additional, Rédini, F., additional, Marec-Bérard, P., additional, Pacquement, H., additional, Lervat, C., additional, Gentet, J., additional, Entz-Werlé, N., additional, Italiano, A., additional, Corradini, N., additional, Bompas, E., additional, Penel, N., additional, Tabone, M., additional, De Pinieux, G., additional, Petit, P., additional, Buffard, K., additional, Blay, J., additional, and Brugières, L., additional

Published
2014
Full Text
View/download PDF

35. Treatment of Children and Adolescents with Classical Hodgkin Lymphoma: Final Results of SFCE MDH03 Study

Author

Seror, E, primary, Lambilliotte, A, additional, Pacquement, H, additional, Gaspar, N, additional, Schell, M, additional, Plat, G, additional, Curtillet, C, additional, Reguerre, Y, additional, Vaudre, G, additional, Haouy, S, additional, Helfre, S, additional, Gorde-Grosjean, S, additional, Schmitt, C, additional, Aladjidi, N, additional, Boudjemaah, S, additional, Claude, L, additional, Donadieu, J, additional, Landman-Parker, J, additional, and Leblanc, T, additional

Published
2014
Full Text
View/download PDF

37. Malformations, genetic abnormalities, and wilms tumor

Author

Dumoucel, S., primary, Gauthier-Villars, M., additional, Stoppa-Lyonnet, D., additional, Parisot, P., additional, Brisse, H., additional, Philippe-Chomette, P., additional, Sarnacki, S., additional, Boccon-Gibod, L., additional, Rossignol, S., additional, Baumann, C., additional, Aerts, I., additional, Bourdeaut, F., additional, Doz, F., additional, Orbach, D., additional, Pacquement, H., additional, Michon, J., additional, and Schleiermacher, G., additional

Published
2013
Full Text
View/download PDF

39. Use of Off-Label Targeted Therapies in Refractory Sarcomas: Analysis of Pediatric Data from the French Registry Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes.

Author

Garnier, Nathalie, Bertrand, A., Libbrecht, C., Corradini, N., Pacquement, H., Gentet, J. C., Lervat, C., Girodet, M., Bouclier, L., Ray-Coquard, I., and Marec-Berard, P.

Subjects
SARCOMA
Abstract

Targeted therapies (TT) are used in pediatric patients based on the data from adult literature. In 2008, the French Sarcoma Study Group and the Bone Tumor Group (Groupe Sarcome Français-Groupe d'étude des Tumeurs Osseuses) opened Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes (OUTC'S), a national registry of targeted off-label sarcomas therapies. All patients registered in the OUTC'S database and treated in pediatric oncology units were included in this analysis. We describe TTs using off-label and off clinical trial practices for children with sarcoma. We analyzed TT tolerability and efficacy for 34 patients with osteosarcoma (n = 20), Ewing sarcoma (n = 9), clear cell sarcoma (n = 1), synovialsarcoma (n = 1), epithelioid sarcoma (n = 1), myofibroblastic tumor (n = 1), and desmoid tumor (n = 1) who were registered from six pediatric centers. In total, 38 different TT courses were administered. The median age was 15 years (5-23) and 18.5 years (7-27) at diagnosis and at the time of starting TT, respectively. The decision to initiate TT was taken in a multidisciplinary board in 92% of the cases. TT included sirolimus (alone or in association with other treatments), sunitinib, sorafenib, cetuximab, imatinib, and crizotinib. The median duration of treatment was 109 days (21-515). Of the 34 patients, 6 had a partial response with a median response duration of 3.72 months (2.08-30.8) and 10 had a stabilization of the disease with a median duration of 3.63 months (0.75- 16.89). In our cohort, overall survival and progression-free survival were 8.68months (95% confidence interval [CI]: 5.85-11.50) and 3.29 months (95% CI: 2.69-3.88), respectively. Grades 3 and 4 toxicities were reported for seven patients (26%) and were most commonly hematological. Patients under 15 years of age did not show severe toxicity. Hence, TT is an acceptable therapeutic option for refractory pediatric sarcomas. It is very important to continue collecting data and develop phase I/II protocols. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

42. CL099 - Évaluation des recommandations MDH03 pour le traitement des lymphomes de Hodgkin de l’enfant

Author

Seror, E., primary, Leblanc, T., additional, Lambilliotte, A., additional, Pacquement, H., additional, Donadieu, J., additional, Schell, M., additional, Robert, A., additional, André, N., additional, Gorde-Grosjean, S., additional, Schmitt, C., additional, Edan, C., additional, Perel, Y., additional, Carrie, C., additional, Oberlin, O., additional, and Landman-Parker, J., additional

Published
2010
Full Text
View/download PDF

43. [Platinum derivatives in pediatric oncology]

Author

François Doz, Pinkerton R, Pacquement H, Michon J, Quintana E, Bastian G, Chazard M, Pellae-Cosset B, and Jm, Zucker

Subjects
Neoplasms, Humans, Cisplatin, Child, Carboplatin
Published
1993

44. Mortalité globale et par maladies cardiovasculaires à long terme après traitement d’un cancer de l’enfant : rôle du traitement

Author

Tukenova, M., primary, Guibout, C., additional, Oberlin, O., additional, Doyon, F., additional, Moussannif, A., additional, Haddy, N., additional, Guérin, S., additional, Pacquement, H., additional, Aoubae, A., additional, Hawkins, M., additional, Winterf, D., additional, Bourhis, J., additional, Lefkopoulos, D., additional, Diallo, I., additional, and de Vathaire, F., additional

Published
2008
Full Text
View/download PDF

47. [Multidrug resistance of solid tumors in children]

Author

François Doz, Michon J, Quintana E, Pacquement H, and Jm, Zucker

Subjects
Gene Expression Regulation, Neoplastic, Neuroblastoma, Membrane Glycoproteins, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Rhabdomyosarcoma, Drug Resistance, Humans, Infant, Child, Vinca Alkaloids, Intercalating Agents, Podophyllotoxin
Published
1991

48. Hypercalcémie chez l'enfant cancéreux

Author

Kerdudo, C., primary, Aerts, I., additional, Fattet, S., additional, Chevret, L., additional, Pacquement, H., additional, Doz, F., additional, Michon, J., additional, Garabedian, M., additional, and Orbach, D., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results